Two leading Indian pharmaceutical companies, Sun Pharma and Lupin, have initiated drug recalls in the US market due to separate manufacturing issues identified by the US Food and Drug Administration (USFDA).
Sun Pharma is recalling over 96,000 bottles of Liothyronine Sodium Tablets, used for treating hypothyroidism, after failing tests for impurities and degradation. The affected batches pose no immediate health risk, but the company is taking precautionary measures to ensure patient safety.
**Lupin** is recalling an unspecified quantity of Penicillamine tablets, a treatment for Wilson’s disease, due to a manufacturing issue discovered during routine inspections. Details regarding the specific concern and potential health risks are currently unavailable.
Both companies have notified the USFDA and are actively implementing the recalls. They are also working with distributors and retailers to retrieve the affected products from the market.
This incident highlights the importance of stringent quality control measures in the pharmaceutical industry. While minor recalls are not uncommon, incidents involving major players like Sun Pharma and Lupin can raise concerns about potential systemic issues within the manufacturing process. The USFDA is expected to investigate the root cause of these recalls and may take further action depending on the severity of the identified issues.